Subscribe
istock-664752920_solovyova
solovyova / iStockphoto.com
4 May 2018Americas

Federal Circuit affirms PTAB’s rejection of dog mobility patent

The US Court of Appeals for the Federal Circuit has confirmed that individuals need not have contributed equally to be considered joint inventors of patentable subject matter, in a case involving a dog mobility device.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Zoetis sues rival over generic pet vomiting treatment
21 September 2021   Veterinary drug maker Dechra’s generic of a drug that treats vomiting in dogs and cats, Cerenia, infringes a patent owned by its competitor Zoetis, a new lawsuit has alleged.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Generics
Zoetis sues rival over generic pet vomiting treatment
21 September 2021   Veterinary drug maker Dechra’s generic of a drug that treats vomiting in dogs and cats, Cerenia, infringes a patent owned by its competitor Zoetis, a new lawsuit has alleged.

More on this story

Generics
Zoetis sues rival over generic pet vomiting treatment
21 September 2021   Veterinary drug maker Dechra’s generic of a drug that treats vomiting in dogs and cats, Cerenia, infringes a patent owned by its competitor Zoetis, a new lawsuit has alleged.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York